logo
Overview
Discover
Watchlists
Portfolios
Heatmap
Sectors
Trendscore
Performers
Alerts
Options
Earnings
Screeners
Scanners
Backtests
Strategies
Comparisons
Charts
Sign in
Discover
KZR
Kezar Life Sciences, Inc.
7.29
1 x 7.24
1 x 7.41
bid
ask
+
0.00
0.00%
04:00 PM
timesize
Ytd15.90%
1y72.75%
7.27
day range
7.47
3.53
52 week range
7.55
Open7.36Prev Close7.29Low7.27High7.47Mkt Cap53.86M
Vol0.00Avg Vol87.93KEPS-6.17P/E-1.18Forward P/E-0.62
Beta0.40Short Ratio0.93Inst. Own63.90%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning08-1250-d Avg7.13200-d Avg5.811yr Est13.50

KZR News

$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—KZR, FORA, SLNO, and APLS
globenewswire.com
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—KZR, FORA, SLNO, and APLS

NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde a

Are APLS, CNTA, KZR Obtaining Fair Deals for their Shareholders?
prnewswire.com
Are APLS, CNTA, KZR Obtaining Fair Deals for their Shareholders?

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following compan

Shareholder Alert: Ademi LLP investigates whether Kezar Life Sciences, Inc. is obtaining a Fair Price for Public Shareholders
globenewswire.com
Shareholder Alert: Ademi LLP investigates whether Kezar Life Sciences, Inc. is obtaining a Fair Pric

MILWAUKEE, April 07, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating Kezar (NASDAQ: KZR) for pos

Lifecore Biomedical (NASDAQ:LFCR) and Kezar Life Sciences (NASDAQ:KZR) Head-To-Head Review
defenseworld.net
Lifecore Biomedical (NASDAQ:LFCR) and Kezar Life Sciences (NASDAQ:KZR) Head-To-Head Review

Kezar Life Sciences (NASDAQ: KZR - Get Free Report) and Lifecore Biomedical (NASDAQ: LFCR - Get Free

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Kezar Life Sciences, Inc. (NASDAQ: KZR)
prnewswire.com
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Kezar Life Sciences, Inc.

NEW YORK, March 30, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & As

Shareholder Alert: The Ademi Firm investigates whether Kezar Life Sciences, Inc. is obtaining a Fair Price for Public Shareholders
prnewswire.com
Shareholder Alert: The Ademi Firm investigates whether Kezar Life Sciences, Inc. is obtaining a Fair

MILWAUKEE, March 30, 2026 /PRNewswire/ -- Ademi LLP is investigating Kezar (NASDAQ: KZR) for possibl

KZR Stock Alert: Halper Sadeh LLC is Investigating Whether Kezar Life Sciences, Inc. is Obtaining a Fair Price for its Shareholders
businesswire.com
KZR Stock Alert: Halper Sadeh LLC is Investigating Whether Kezar Life Sciences, Inc. is Obtaining a

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale

Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right
businesswire.com
Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingen

ROCKVILLE, Maryland & EDMONTON, Alberta & SOUTH SAN FRANCISCO, California--(BUSINESS WIRE)--Aurinia

Kezar Life Sciences, Inc. (NASDAQ:KZR) Given Consensus Recommendation of “Reduce” by Brokerages
defenseworld.net
Kezar Life Sciences, Inc. (NASDAQ:KZR) Given Consensus Recommendation of “Reduce” by Brokerages

Kezar Life Sciences, Inc. (NASDAQ: KZR - Get Free Report) has earned a consensus recommendation of "

Enodia Therapeutics Strengthens Sec61 Portfolio Through Acquisition of Preclinical Assets from Kezar Life Sciences
businesswire.com
Enodia Therapeutics Strengthens Sec61 Portfolio Through Acquisition of Preclinical Assets from Kezar

PARIS & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #Biotech--Enodia Therapeutics, a biotechnolog

BML Capital Management LLC Has $2.81 Million Holdings in Kezar Life Sciences, Inc. $KZR
defenseworld.net
BML Capital Management LLC Has $2.81 Million Holdings in Kezar Life Sciences, Inc. $KZR

BML Capital Management LLC boosted its holdings in Kezar Life Sciences, Inc. (NASDAQ: KZR) by 13.5%

Kezar Life Sciences, Inc. (NASDAQ:KZR) Receives Consensus Rating of “Reduce” from Analysts
defenseworld.net
Kezar Life Sciences, Inc. (NASDAQ:KZR) Receives Consensus Rating of “Reduce” from Analysts

Shares of Kezar Life Sciences, Inc. (NASDAQ: KZR - Get Free Report) have been given an average ratin

Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis
businesswire.com
Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq:KZR), a clinical-sta

Kezar Life Sciences (KZR) Upgraded to Buy: Here's What You Should Know
zacks.com
Kezar Life Sciences (KZR) Upgraded to Buy: Here's What You Should Know

Kezar Life Sciences (KZR) might move higher on growing optimism about its earnings prospects, which

Kezar Life Sciences, Inc. (NASDAQ:KZR) Receives Average Recommendation of “Reduce” from Brokerages
defenseworld.net
Kezar Life Sciences, Inc. (NASDAQ:KZR) Receives Average Recommendation of “Reduce” from Brokerages

Shares of Kezar Life Sciences, Inc. (NASDAQ: KZR - Get Free Report) have received an average recomme

Reviewing Dyadic International (NASDAQ:DYAI) and Kezar Life Sciences (NASDAQ:KZR)
defenseworld.net
Reviewing Dyadic International (NASDAQ:DYAI) and Kezar Life Sciences (NASDAQ:KZR)

Dyadic International (NASDAQ: DYAI - Get Free Report) and Kezar Life Sciences (NASDAQ: KZR - Get Fre

Kezar Life Sciences Reports Third Quarter 2025 Financial Results
businesswire.com
Kezar Life Sciences Reports Third Quarter 2025 Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-st

Kezar Life Sciences Announces Presentation of PORTOLA Data at the American Association for the Study of Liver Disease (AASLD) – The Liver Meeting® 2025
businesswire.com
Kezar Life Sciences Announces Presentation of PORTOLA Data at the American Association for the Study

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-st
benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session

Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis and Plans to Explore Strategic Alternatives
businesswire.com
Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis and

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR, the Company),

benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
benzinga.com
Stocks That Hit 52-Week Lows On Thursday

  On Thursday, 369 companies hit new 52-week lows.
benzinga.com
Stocks That Hit 52-Week Lows On Wednesday

  On Wednesday, 311 stocks hit new 52-week lows.
benzinga.com
Stocks That Hit 52-Week Lows On Thursday

  During the session on Thursday, 461 stocks hit new 52-week lows.
benzinga.com
Stocks That Hit 52-Week Lows On Monday

  During Monday's trading, 1214 companies set new 52-week lows.